Clinical Trial Update: A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis. [Phase 2]

View source ↗

Summary

Phase II study of SB-751689 in post-menopausal osteoporosis was terminated. Results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• SB-751689 (SB-751689)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Osteoporosis | Phase 2 | Status: TERMINATED | Results posted: 2017-09-05